绥美凯进医保了吗

The recommended dosage of Suimeike (Dolutea Abalamib Tablets) is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given this product because this product is a fixed-dose tablet and the dose cannot be reduced. Trimax (dolutegravir or lamivudine) is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir or lamivudine can be used. In these cases, physicians should refer to the respective product information for these drugs. Today let’s learn more about Suimeikai’s medical insurance?

According to Medical Companion Travel, Suimeikai (Domitabalamid Tablets) has just been launched in China and has not yet been included in medical insurance, and it is not yet a medical insurance drug. Since Suimeike (Dolutea Paramid Tablets) is an imported original drug in China, it is very expensive and most patients cannot afford it. Therefore, many patients choose Suimeikai (Domitabalamid Tablets), which is available in India. Suimeike (Doteta abalami tablets) produced by the Indian company Emcure, comes in a box of 30 tablets, priced at approximately RMB 1,000. Due to the floating exchange rate, the price cannot be determined. Please consult Medical Travel for specific prices.

Suimeike (dolute abalamide tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation Trimeq (dolute abalamib tablets) with the new generation integrase inhibitor dolutegravir (DTG) as the core for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

Suimeike (dolutegravir tablets) is the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of high efficacy, good tolerance, high resistance barrier, and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

The above is the content of the medical insurance for Suimeikai (Doteta Abalamid Tablets), I hope it can help you!